Immunocore Holdings plc
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $115.9M | $106.7M | $104.5M | $103.7M | $98.0M | $93.9M | $84.1M | $80.2M |
| Cost of Revenue | $1.1M | $434.0K | $2.7M | $513.0K | $1.0M | $831.0K | $330.0K | $448.0K |
| Gross Profit | $114.8M | $106.2M | $101.8M | $103.2M | $96.9M | $93.1M | $83.7M | $79.8M |
| Gross Margin | 99.1% | 99.6% | 97.4% | 99.5% | 98.9% | 99.1% | 99.6% | 99.4% |
| Operating Expenses | ||||||||
| Research & Development | $73.9M | $61.1M | $78.8M | $70.6M | $69.0M | $56.5M | $60.9M | $52.8M |
| SG&A Expense | $43.9M | $37.9M | $42.6M | $39.8M | $42.8M | $40.2M | $42.3M | $35.5M |
| Operating Income | $-3.0M | $7.3M | $-19.7M | $-7.2M | $-14.9M | $-3.6M | $-19.5M | $-8.5M |
| Operating Margin | -2.6% | 6.8% | -18.8% | -6.9% | -15.2% | -3.9% | -23.1% | -10.6% |
| Interest Expense | $3.1M | $3.1M | $3.1M | $3.0M | $3.0M | $3.0M | $7.0M | $4.3M |
| Pretax Income | $-514.0K | $13.3M | $-15.8M | $304.0K | $-9.7M | $6.1M | $-24.8M | $6.1M |
| Income Tax Expense | $294.0K | $301.0K | $14.3M | $481.0K | $606.0K | $1.1M | $-1.1M | $-2.6M |
| Net Income | $-808.0K | $13.0M | $-30.1M | $-177.0K | $-10.3M | $5.0M | $-23.8M | $8.7M |
| Net Margin | -0.7% | 12.2% | -28.8% | -0.2% | -10.5% | 5.4% | -28.3% | 10.9% |
| EPS (Basic) | $-0.02 | $0.26 | $-0.61 | $0.00 | $-0.20 | $0.10 | $-0.47 | $0.17 |
| EPS (Diluted) | $-0.02 | $0.25 | $-0.61 | $0.00 | $-0.20 | $0.10 | $-0.47 | $0.17 |
| Shares Outstanding (Basic) | 51.0M | 50.8M | 50.3M | 50.4M | 50.3M | 50.1M | 50.0M | 50.0M |
| Shares Outstanding (Diluted) | 51.0M | 52.9M | 50.3M | 50.4M | 50.3M | 51.9M | 50.0M | 52.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |